Concepedia

Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non–Small Cell Lung Cancer: Comparison of Assessment Methods

Narjess Ayati, Sze Ting Lee, Seyed Rasoul Zakavi, Melissa Cheng, Eddie Lau, Sagun Parakh, Kunthi Pathmaraj, Andrew M. Scott

Journal of Nuclear Medicine · 2020 · 31 citations · 17 references

DOIFull text

Open access

Concepts

Abstract

F-FDG-avid lesion according to PERCIST and imPERCIST accurately reflects the overall metabolic response.

References

17

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian, Mario Sznol, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 2.2K citations

, , +17

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · Journal of Clinical Oncology · 2014 · 1.1K citations · Full text

, , +17

Pseudoprogression and Immune-Related Response in Solid Tumors

Victoria L. Chiou, Mauricio Burotto · Journal of Clinical Oncology · 2015 · 909 citations

, , +17

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

Mizuki Nishino, Anita Giobbie‐Hurder, Maria Gargano et al. · Clinical Cancer Research · 2013 · 522 citations · Full text

, , +15

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

Mélodie Tazdait, Laura Mezquita, J. Lahmar et al. · European Journal of Cancer · 2017 · 351 citations

, , +14